Holmusk
Total Raised
$31.3MInvestors Count
8Deal Terms
1Holmusk Funding, Holmusk Valuation & Holmusk Revenue
6 Fundings
Holmusk's latest funding round was a Series B for on December 6, 2021.
Holmusk's valuation in September 2018 was $30M.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
---|---|---|---|---|---|---|
12/6/2021 | Series B | 1 | ||||
5/18/2020 | Series A | |||||
5/25/2019 | Incubator/Accelerator - II | |||||
4/18/2019 | Incubator/Accelerator | |||||
9/25/2018 | Seed VC | $30M |
Date | 12/6/2021 | 5/18/2020 | 5/25/2019 | 4/18/2019 | 9/25/2018 |
---|---|---|---|---|---|
Round | Series B | Series A | Incubator/Accelerator - II | Incubator/Accelerator | Seed VC |
Amount | |||||
Investors | |||||
Valuation | $30M | ||||
Revenue | |||||
Sources | 1 |
Holmusk Deal Terms
1 Deal Term
Holmusk's deal structure is available for 1 funding round, including their Seed VC from September 25, 2018.
Round | Seed VC |
---|---|
Funding Date | |
Pre-Money Valuation | |
Post-Money Valuation | |
Amount Raised | |
Shares Authorized | |
Issuance Price | |
Dividend Rate | |
Liquidation Preferences | |
Liquidation Price | |
Participation | |
Conversion Price | |
Anti Dilution | |
General Voting | |
Board Voting | |
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Seed VC |
Holmusk Investors
8 Investors
Holmusk has 8 investors. Heritas Capital invested in Holmusk's Series B funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
---|---|---|---|---|---|---|
9/25/2018 | 12/6/2021 | 3 Seed VC, Series A (2020), Series B (2021) | Venture Capital | Singapore | ||
Venture Capital | New York | |||||
Corporate Venture | California | |||||
Venture Capital | Switzerland | |||||
Corporate Venture | New York |
First funding | 9/25/2018 | ||||
---|---|---|---|---|---|
Last Funding | 12/6/2021 | ||||
Investor | |||||
Rounds | 3 Seed VC, Series A (2020), Series B (2021) | ||||
Board Seats | |||||
Type | Venture Capital | Venture Capital | Corporate Venture | Venture Capital | Corporate Venture |
Location | Singapore | New York | California | Switzerland | New York |
Holmusk Acquisitions
1 Acquisition
Holmusk acquired 1 company. Their latest acquisition was Otsuka Health Solutions on April 27, 2021.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
4/27/2021 | Other | Acquired | 2 |
Date | 4/27/2021 |
---|---|
Investment Stage | Other |
Companies | |
Valuation | |
Total Funding | |
Note | Acquired |
Sources | 2 |
You May Also Like

Virta Health develops a clinically-proven treatment to safely and sustainably reverse type 2 diabetes and other chronic metabolic diseases without the use of medications or surgery.

Vida Health is a virtual care company that combines a human-centric approach with technology to address chronic physical and behavioral health conditions. The company provides personalized digital therapeutic programs combined with real human health coaching & therapy through a mobile & online platform that supports individuals in managing & reversing conditions such as diabetes, hypertension, obesity, depression, anxiety, stress, asthma, & more. The platform integrates individual expert care with machine learning & remote monitoring to deliver lasting behavior change, health outcomes & cost savings.

Glooko's universal diabetes software products provide insights to improve outcomes for people with diabetes and their care teams. Glooko's systems synchronize data from more than 190 diabetes devices and activity trackers, and they deliver integrated, timely and useful patient data, including glucose levels, blood pressure, weight, and food, insulin and medication intake.

Canary Health is a provider of digital health self-management programs which includes a CDC approved online diabetes prevention program and a chronic disease self-management program.

WellDoc is a healthcare behavioral science and technology company that focuses on simplifying the way chronic diseases are managed through a collaborative approach that breaks down the barriers of engagement and adherence by providing patients and healthcare providers with real-time information. WellDoc has developed a technology-based solution designed to help people with chronic diseases better manage conditions. The flagship product, DiabetesManager, provides a system for patients and health care providers to coordinate diabetes care, propel self-management and achieve long-term adherence.

Wellocity Health is a digital therapeutics company that offers a telehealth platform to organizations for delivering evidence-based personalized lifestyle change programs focused on preventing diabetes and heart disease.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.